Neobes

Amfepramone

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neobes

What is Neobes? Overview

Property	Description
Active ingredient	Amfepramone (Diethylpropion)
Form	Oral tablet (typically extended-release)
Pharmacological class	Anorexigenic Agent, Sympathomimetic Amine
General purpose	Appetite suppression
Origin	Synthetic agent

Neobes is a synthetic, prescription-only medication containing the active ingredient Amfepramone, a substance also known internationally as Diethylpropion. It is classified pharmacologically as a sympathomimetic amine and an anorexigenic agent, which places it within the family of medications designed to influence hunger signals centrally. Its primary general purpose is to facilitate appetite suppression, serving as an adjunctive component in a medically supervised program for short-term weight management based on caloric restriction.

Definition, Composition, and Classification

The medicinal entity Neobes is a monotherapy, meaning it contains Amfepramone as its sole active ingredient. This compound is chemically identified as a phenethylamine derivative. The World Health Organization (WHO) assigns it the Anatomical Therapeutic Chemical (ATC) code A08AA03, designating it as a centrally acting antiobesity preparation. This distinction confirms the drug's established function within medical practice.

General Purpose and Mechanism Principle

Amfepramone is clinically recognized for its utility in reducing excessive caloric intake. The drug is often presented as an oral tablet, frequently in an extended-release formulation, a design feature intended to sustain its effect throughout the day. It works by acting on appetite control centers within the hypothalamus, where it facilitates the release and reuptake inhibition of neurotransmitters such as norepinephrine. This specific mechanism principle is intended to amplify the brain's signals of satiety and fullness, thereby reducing the patient's desire to consume food and supporting controlled dietary intake.

What side effects are possible with Neobes?

Possible Side Effects and Safety Information

The official safety profile for Amfepramone (Diethylpropion), the active ingredient in Neobes, is primarily defined by its effects on the central nervous and cardiovascular systems, consistent with its classification as a sympathomimetic amine. Adverse reactions are grouped by severity and the affected organ system, according to governmental regulatory documentation.

Adverse Reaction Classification

Classification	System-Organ Class Affected
Common	Central Nervous System (e.g., nervousness, insomnia, headache), Gastrointestinal System (e.g., dry mouth, constipation)
Rare	Cardiovascular (e.g., Pulmonary Hypertension, Valvular Heart Disease), Psychiatric (e.g., toxic psychosis, hallucinations)

The most frequently reported side effects in official labels include insomnia, dry mouth, nervousness, and constipation.

Serious Safety Constraints

The medication is subject to severe restrictions due to the risk of rare, serious adverse events. Pulmonary Hypertension is a life-threatening risk associated with anorectic agents, particularly when used for longer than three months. Amfepramone is formally classified as a Schedule IV controlled substance, which reflects its documented potential for abuse and dependence.

Strict contraindications apply based on pre-existing conditions. Use is forbidden in patients with severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or a history of drug abuse. The safety and effectiveness of the medicine have not been established for pediatric patients under 16 years of age.

Overdose and Emergency Response

The regulatory documentation for Neobes (Amfepramone/Diethylpropion) strictly defines the manifestations and required emergency actions for overdosage.

Acute overdosage is documented by initial signs of central nervous system (CNS) stimulation, including restlessness, tremor, hyperreflexia, panic states, confusion, and mydriasis. This excitatory phase may be followed by CNS depression, manifesting as fatigue and depression.

Severe outcomes noted in the official profile include critical cardiovascular effects such as arrhythmias, severe hypertension or hypotension, and circulatory collapse. Overdose of pharmacologically similar compounds has resulted in convulsions, coma, and death. Manifestations of chronic intoxication include the official documentation of severe psychosis and dermatoses.

Management of acute intoxication is defined as symptomatic and supportive treatment, including the use of lavage and activated charcoal to reduce absorption. No specific antidote is known for this intoxication.

Regulatory guidance mandates that if acute overdosage is suspected, immediate medical attention must be sought by contacting emergency services or a poison control center. Urgent hospitalization and monitoring are required if signs of severe systemic compromise, such as seizures, loss of consciousness, or trouble breathing, are observed.

Therapeutic Uses of Neobes

What Neobes Treats: Main Uses and Benefits

Neobes (Amfepramone) is primarily used to address the key symptomatic domain of excessive and persistent hunger signals that often undermine weight loss attempts. It provides supportive relief by moderating these signals, which may help patients cope more steadily with the difficult, early stages of adhering to a prescribed low-calorie diet.

The medication is commonly used as a supportive measure in situations involving exogenous obesity and for high-risk overweight patients with comorbidities. It is applied when diet and exercise alone have proven insufficient to achieve necessary reduction. The benefit contributes to improving weight management goals and physical measurements like waist circumference.

“It is a supportive tool intended to enhance the initial compliance with dietary restriction, a cornerstone of short-term weight management.”

Quick Fact: Relief for Excessive Appetite

Regulatory References

NIH DailyMed official indication

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Neobes (Amfepramone)

Eligibility for Neobes (Amfepramone) is strictly defined by regulatory agencies. The medication is generally intended for adults and adolescents 17 years of age and older. Use is officially not recommended for children 16 years and younger, as safety and efficacy have not been established in this age group. Elderly patients require caution due to the higher likelihood of age-related organ dysfunction.

Absolute Contraindications

Use of Neobes is strictly contraindicated in patients with specific pre-existing conditions, including:

Cardiovascular Conditions: Pulmonary hypertension, severe hypertension, advanced arteriosclerosis, or known valvular heart disease.
Endocrine/Ocular Conditions: Hyperthyroidism or glaucoma.
Psychiatric/Substance History: Agitated states or a documented history of drug abuse or dependence.
Concurrent Medication: Use with MAO Inhibitors (within 14 days of administration) or in combination with any other anorectic agents.

Conditional Use and Reproductive Status

Patients with mild to moderate hypertension or epilepsy require careful monitoring. For pregnant patients, use is not recommended due to potential risks. Use during lactation requires a careful assessment of risks versus potential benefits.

What should I know about interactions with other medicines?

Neobes (Amfepramone) possesses officially documented interaction patterns that establish specific constraints on co-administration with various medicinal products and substances. Regulatory authorities classify the combination with Monoamine Oxidase Inhibitors (MAOIs) as contraindicated due to the severe risk of hypertensive crisis; a minimum 14-day separation period is required after discontinuation of an MAOI. Furthermore, combining Neobes with other anorectic agents, including certain herbal products or prescription diet preparations, is also strictly contraindicated due to the potential for serious cardiac complications.

Documented pharmacodynamic risks include additive effects with alcohol and other CNS Depressants, which may increase central nervous system side effects. Use with General Anesthetics is officially associated with an increased risk of cardiac arrhythmias. The medication also exhibits potential for antagonism of its anorectic effect by co-administered Phenothiazines, and it may decrease the efficacy of co-administered Antihypertensive Drugs.

A key pharmacokinetic interaction involves substances that cause urinary alkalinization (such as Acetazolamide), which decrease the renal excretion rate of Amfepramone. This modification results in a higher circulating concentration of the drug (increased exposure), a constraint specifically noted in official prescribing information.

Mechanism of Action

Neobes functions as an indirect sympathomimetic amine primarily within the central nervous system (CNS). Its core action involves the inhibition of the reuptake of norepinephrine (NE) and dopamine (DA) at the synaptic cleft, concurrent with the stimulation of their release from presynaptic neurons. The resulting elevated synaptic concentration of these neurotransmitters leads to their agonism of postsynaptic receptors in the hypothalamus and associated limbic areas. Specifically, this dual neurochemical modulation drives the downstream agonism of beta-1 and beta-2 adrenergic receptors and alpha-adrenergic receptors within the CNS to produce the anorectic effect. Beyond the CNS, the compound's agonism of peripheral alpha-adrenergic receptors and its activation of the beta-3 adrenergic pathway induce effects consistent with increased systemic metabolic activity through the established sympathetic cascade.

Dosage and Administration Information

How to Use Neobes — Official Administration Guidelines

Neobes (Amfepramone hydrochloride, also known as diethylpropion) must be taken exactly as prescribed by a healthcare provider. The official instructions for its use are defined by the specific dosage form—either immediate-release or controlled/extended-release—and adherence to a short-term treatment course.

Administration Details

Field	Instruction
Route of Administration	Oral.
Dosing Schedule	Immediate-Release (e.g., 25 mg): 25 mg by mouth three times daily. Controlled-Release (e.g., 75 mg): 75 mg by mouth once daily.
Timing in Relation to Meals	Immediate-Release: Taken one hour before meals. Controlled-Release: Taken once daily, usually in the mid-morning.
Preparation Requirement	Controlled-Release: The tablet must be swallowed whole. It must not be crushed, chewed, or divided.
Special Administration	The last dose of the day (especially for immediate-release forms) should be taken several hours before bedtime to avoid possible sleep disruption. Treatment is typically limited to a few weeks.
Missed Dose Rule	If a dose is missed, skip the missed dose and continue with the regular dosing schedule. Do not take two doses at the same time to compensate for a missed dose.

Population and Course Duration

Age-Group Administration: For the geriatric population, use should be approached with caution, often starting at the lower end of the dosing range. Course Duration: Continued use is officially advised only if a patient demonstrates satisfactory response within the first four weeks of treatment. The full course is generally prescribed as a short-term adjunct.

Recent Clinical Evidence

Research evidence / Overview of Studies for Neobes (Amfepramone)

Evidence for Use in Short-Term Weight Management (Exogenous Obesity)

Research exploring Amfepramone alongside a prescribed low-calorie diet has focused on short-term Randomized Controlled Trials (RCTs). These studies were generally applied in research contexts involving adults diagnosed with obesity or high-risk overweight. The intent of these trials was to observe how outcomes related to weight were monitored over time when study participants received the medication compared to when they received a placebo (inactive pill).

Studies monitored several key metrics, including changes in total body weight and the proportion of patients who reached specific weight reduction milestones, such as 5% of their initial body weight. Research also examined changes in physical measurements like waist circumference. Studies monitored changes in weight, and the findings described a distinction in measured weight outcomes between the study group that received the medication and the group that received the placebo. These data contribute to the evidence landscape for medications studied for this use.

Follow-up Duration and Long-Term Research

Research exploring short-term symptom changes was studied for periods typically lasting 12 weeks or less in many foundational trials. The initial evidence was largely based on studies with short-term observation periods.

Data are still emerging, and certainty remains low regarding long-term outcomes. While some trials did include open-label extension phases where patients were observed for up to a year, the controlled research exploring the durability of the measured outcomes over periods exceeding six months is limited. This means that the long-term effects are not fully established, particularly regarding the monitoring of weight outcomes after the study medication ceased.

Evidence in Specific Patient Populations and Limitations

Amfepramone was evaluated in specific adult populations, including individuals defined by clinical guidelines as having high-risk overweight or obesity. Some research has examined patient groups who had specific, controlled comorbidities, such as hypertension or high cholesterol, to evaluate measured outcomes in these individuals. However, evidence is limited for use in special populations such as older adults, and data for long-term use in adolescents remains insufficient according to regulatory summaries.

Systematic reviews note that while many studies were conducted, several older ones had modest sample sizes and the methodology used meant that a high or unclear risk of bias was observed in some studies. This variability means the synthesis of evidence must be approached cautiously. A primary uncertainty is the question of long-term clinical relevance, especially concerning long-term follow-up of metabolic and cardiovascular parameters.

Key Studies & References

How should Neobes be stored and disposed of?

Official Storage Requirements

Storage Condition	Requirement
Temperature	Store at controlled room temperature (typically 20 C to 25 C).
Environmental Control	Protect from excess heat, moisture, and freezing (do not store in a bathroom).
Packaging	Keep the product in the original container, which must be kept tightly closed at all times.
Child Protection	Mandatory to store out of the sight and reach of children using a securely fastened safety cap.

Approved Disposal Instructions

Due to its classification, Neobes must be disposed of according to strict guidelines to prevent misuse and environmental impact. The officially preferred method is to utilize a community drug take-back program. It is strictly prohibited to flush the tablets down the sink or toilet. If a take-back option is unavailable, the medication must be mixed with an undesirable substance (such as used coffee grounds) and sealed in a container before being placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.